ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 2523

Biological Treatment May Be an Option as First Steroid-Sparing Agent in a Subgroup of Young Takayasu Arteritis Patients with Prominent Acute Phase Reactants and Constitutional Symptoms

Sema Kaymaz-Tahra1, Ozun Bayindir Tsechelidis2, Burak Ince3, Ozlem Ozdemir-Isik4, Muhammet Emin Kutu5, Ozlem Karakas6, Tuba Demirci-Yildirim7, Zeliha Ademoglu8, Elif Ediboglu9, Burcu Ceren Uludogan10, Nazife Sule yaşar Bile10, Timucin Kasifoglu11, Servet Akar12, Hakan Emmungil8, Fatos Onen7, Ahmet Omma13, Nilüfer Alpay Kanıtez14, Ayten Yazici15, Ayse Cefle15, Murat Inanc3, Kenan Aksu16, Gokhan Keser17, Haner Direskeneli18 and Fatma Alibaz Öner18, 1Bahcesehir University Faculty of Medicine, Istanbul, Turkey, 2Ottawa University, Ottawa, ON, Canada, 3Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, 4Kocaeli University Faculty of Medicine, Kocaeli, Turkey, 5Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey, 6Ankara City Hospital, Ankara, Turkey, 7Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, 8Trakya University, Edirne, Turkey, 9Mayo Clinic, Rochester, MN, 10Osmangazi University Faculty of Medicine, Rheumatology, Eskişehir, Turkey, Eskisehir, Turkey, 11Osmangazi University Faculty of Medicine, Eskisehir, Turkey, 12Izmir Katip Celebi University School of Medicine, Izmir, Turkey, 13Ankara Bilkent City Hospital, Ankara, Turkey, 14Koc University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey, 15Kocaeli University Faculty of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, 16Ege University Faculty of Medicine, Izmir, Turkey, 17Ege University School of Medicine, Rheumatology, İzmir, Turkey, Izmir, Turkey, 18Marmara University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey

Meeting: ACR Convergence 2024

Keywords: , ,

Session Information

Date: Monday, November 18, 2024

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: There is no data on which patients biologic immunosuppressive (bIS) treatment should be chosen in Takayasu’s arteritis (TAK). In this study we aimed to assess the characteristics of TAK patients needed biologic treatment during follow-up in daily practice.

Methods: Patients fullfilling the American College of Rheumatology 1990 criteria for TAK and who received conventional ISs (cISs) or bIS were included in this retrospective multicentre study. Demographic and clinical data were collected from patient files. 

Results: We included 329 patients (F/M: 284/45) in the study at last visit. The number of the patients who received bIS was 113 (34%)(89 TNF inhibitors, 24 tocilizumab) and who received only cISs was 216 (66%) during follow-up. Mean age at the end of the follow-up was 43.0±13.5 years and mean follow-up duration was 78.7± 65.8 months. Patients who received bISs were younger compared to patients who received cISs (36.8±11.3 vs 46.2±13.2 years, p< 0.01) at last visit assessment. The frequency of constitutional symptoms at baseline visit was higher in bIS group (85% vs 66%, p< 0.01). Also baseline erythrocyte sedimentation rate (ESR) (bIS vs cIS:  66.7±33.5 vs 45.0±29.1 mm/h, p< 0.01) and CRP levels (19 (0.3-280) vs 12.5 (0.2-286) mg/L, p= 0.002) were higher in patients who were given bIS treatments. Number of relapses were higher in patients who needed bISs during follow-up.

Conclusion: In this study, TAK patients with biologic treatment need during follow-up had more frequent constitutional symptoms and higher acute phase reactants with a higher relapse rate compared to patients receiving cIS treatment. Our results may suggest that in young TAK patients with prominent acute phase reactants and constitutional symptoms at diagnosis, biologic treatment may be an option as the first steroid-sparing agent.

Supporting image 1

Disclosures: S. Kaymaz-Tahra: None; O. Bayindir Tsechelidis: Janssen, 5; B. Ince: None; O. Ozdemir-Isik: None; M. Kutu: None; O. Karakas: None; T. Demirci-Yildirim: None; Z. Ademoglu: None; E. Ediboglu: None; B. Uludogan: None; N. yaşar Bile: None; T. Kasifoglu: None; S. Akar: None; H. Emmungil: None; F. Onen: None; A. Omma: None; N. Alpay Kanıtez: None; A. Yazici: None; A. Cefle: None; M. Inanc: None; K. Aksu: None; G. Keser: None; H. Direskeneli: AbbVie/Abbott, 12, Educational grants, Amgen, 12, Educational grants, Roche, 12, Educational grants, UCB, 12, Educational grants; F. Alibaz Öner: AbbVie/Abbott, 12, Educational grants, Amgen, 12, Educational grants, Roche, 12, Educational grants, UCB, 12, Educational grants.

To cite this abstract in AMA style:

Kaymaz-Tahra S, Bayindir Tsechelidis O, Ince B, Ozdemir-Isik O, Kutu M, Karakas O, Demirci-Yildirim T, Ademoglu Z, Ediboglu E, Uludogan B, yaşar Bile N, Kasifoglu T, Akar S, Emmungil H, Onen F, Omma A, Alpay Kanıtez N, Yazici A, Cefle A, Inanc M, Aksu K, Keser G, Direskeneli H, Alibaz Öner F. Biological Treatment May Be an Option as First Steroid-Sparing Agent in a Subgroup of Young Takayasu Arteritis Patients with Prominent Acute Phase Reactants and Constitutional Symptoms [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/biological-treatment-may-be-an-option-as-first-steroid-sparing-agent-in-a-subgroup-of-young-takayasu-arteritis-patients-with-prominent-acute-phase-reactants-and-constitutional-symptoms/. Accessed .

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/biological-treatment-may-be-an-option-as-first-steroid-sparing-agent-in-a-subgroup-of-young-takayasu-arteritis-patients-with-prominent-acute-phase-reactants-and-constitutional-symptoms/